Why Pharma Boards Confuse Scenario Models With Risk Measurements

InnovationWhy Pharma Boards Confuse Scenario Models With Risk MeasurementsByMaman Ibrahim,Forbes Councils Member.for Forbes Technology CouncilCOUNCIL POSTExpertise from Forbes Councils members, operated under license. Opinions expressed are those of the author. | Membership (fee-based)May 20, 2026, 06:15am EDTMaman Ibrahim is a cyber and digital risk executive, helping boards, CRO, CIO, and CISO turn risk work into decisions, delivery, and proof. gettyA large number can change the weather in a boardroom.The chair looks up. The CFO stops scrolling. Someone who looked calm now studies the paper as if it might bite.The number is £312 million (about $422 million).It comes from a representative oncology pipeline risk scenario informed by pharma industry experience and NPV modeling. In the scenario, a breach involving a third-party clinical platform leads to a modeled £312 million exposure estimate tied to a flagship drug asset. Nobody wants to wave it away.​The number is not fake or reckless. It's in the wrong place.That is how phantom numbers are born: from bad placement. A scenario gets dropped into a risk register, loses its conditions, sheds its probability and enters the boardroom pretending to be a measurement.​​When The Number Is Real But The Label Isn't​In the representative scenario, a clinical platform provider is breached. Attackers access trial data, safety signals and scientific material linked to a flagship oncology asset.The £312 million figure answers a conditional question: What might the company lose if regulators rule the trial data compromised, if a Phase III re-run is required, if launch timing slips and if competitors gain ground?But it’s not the same question as: What has this event cost us, or what can we confidently estimate now?That second question belongs to base-case risk measurement. It covers forensics, regulatory handling, vendor remediation, legal protection and submission support. Those costs live in the present. They may be unc...